Cargando…
First-line Anti-GD2 Therapy Combined With Consolidation Chemotherapy in 3 Patients With Newly Diagnosed Metastatic Ewing Sarcoma or Ewing-like Sarcoma
Despite multimodal therapy, the prognosis of patients with metastatic Ewing sarcoma (ES) remains poor, with new treatments urgently needed. The disialoganglioside GD2, a well-established tumor-associated antigen, is expressed in 40% to 90% of ES cells, making it a suitable therapeutic target. Here w...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9323561/ https://www.ncbi.nlm.nih.gov/pubmed/35622995 http://dx.doi.org/10.1097/MPH.0000000000002488 |
_version_ | 1784756581203705856 |
---|---|
author | Spasov, Neofit J. Dombrowski, Frank Lode, Holger N. Spasova, Mariya Ivanova, Liliya Mumdjiev, Ivan Burnusuzov, Hassan Siebert, Nikolai |
author_facet | Spasov, Neofit J. Dombrowski, Frank Lode, Holger N. Spasova, Mariya Ivanova, Liliya Mumdjiev, Ivan Burnusuzov, Hassan Siebert, Nikolai |
author_sort | Spasov, Neofit J. |
collection | PubMed |
description | Despite multimodal therapy, the prognosis of patients with metastatic Ewing sarcoma (ES) remains poor, with new treatments urgently needed. The disialoganglioside GD2, a well-established tumor-associated antigen, is expressed in 40% to 90% of ES cells, making it a suitable therapeutic target. Here we report 3 cases with newly diagnosed, metastatic, GD2-positive ES or Ewing-like sarcoma treated with the anti-GD2 antibody dinutuximab beta in addition to standard chemotherapeutic regimens. Treatment was well-tolerated, and all patients achieved complete remission, without evidence of relapse. First-line anti-GD2 immunotherapy in patients with metastatic, GD2-positive ES or Ewing-like sarcoma represents a promising therapeutic option that warrants further clinical evaluation. |
format | Online Article Text |
id | pubmed-9323561 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-93235612022-08-03 First-line Anti-GD2 Therapy Combined With Consolidation Chemotherapy in 3 Patients With Newly Diagnosed Metastatic Ewing Sarcoma or Ewing-like Sarcoma Spasov, Neofit J. Dombrowski, Frank Lode, Holger N. Spasova, Mariya Ivanova, Liliya Mumdjiev, Ivan Burnusuzov, Hassan Siebert, Nikolai J Pediatr Hematol Oncol Online Articles: Clinical and Laboratory Observations Despite multimodal therapy, the prognosis of patients with metastatic Ewing sarcoma (ES) remains poor, with new treatments urgently needed. The disialoganglioside GD2, a well-established tumor-associated antigen, is expressed in 40% to 90% of ES cells, making it a suitable therapeutic target. Here we report 3 cases with newly diagnosed, metastatic, GD2-positive ES or Ewing-like sarcoma treated with the anti-GD2 antibody dinutuximab beta in addition to standard chemotherapeutic regimens. Treatment was well-tolerated, and all patients achieved complete remission, without evidence of relapse. First-line anti-GD2 immunotherapy in patients with metastatic, GD2-positive ES or Ewing-like sarcoma represents a promising therapeutic option that warrants further clinical evaluation. Lippincott Williams & Wilkins 2022-08 2022-05-27 /pmc/articles/PMC9323561/ /pubmed/35622995 http://dx.doi.org/10.1097/MPH.0000000000002488 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) |
spellingShingle | Online Articles: Clinical and Laboratory Observations Spasov, Neofit J. Dombrowski, Frank Lode, Holger N. Spasova, Mariya Ivanova, Liliya Mumdjiev, Ivan Burnusuzov, Hassan Siebert, Nikolai First-line Anti-GD2 Therapy Combined With Consolidation Chemotherapy in 3 Patients With Newly Diagnosed Metastatic Ewing Sarcoma or Ewing-like Sarcoma |
title | First-line Anti-GD2 Therapy Combined With Consolidation Chemotherapy in 3 Patients With Newly Diagnosed Metastatic Ewing Sarcoma or Ewing-like Sarcoma |
title_full | First-line Anti-GD2 Therapy Combined With Consolidation Chemotherapy in 3 Patients With Newly Diagnosed Metastatic Ewing Sarcoma or Ewing-like Sarcoma |
title_fullStr | First-line Anti-GD2 Therapy Combined With Consolidation Chemotherapy in 3 Patients With Newly Diagnosed Metastatic Ewing Sarcoma or Ewing-like Sarcoma |
title_full_unstemmed | First-line Anti-GD2 Therapy Combined With Consolidation Chemotherapy in 3 Patients With Newly Diagnosed Metastatic Ewing Sarcoma or Ewing-like Sarcoma |
title_short | First-line Anti-GD2 Therapy Combined With Consolidation Chemotherapy in 3 Patients With Newly Diagnosed Metastatic Ewing Sarcoma or Ewing-like Sarcoma |
title_sort | first-line anti-gd2 therapy combined with consolidation chemotherapy in 3 patients with newly diagnosed metastatic ewing sarcoma or ewing-like sarcoma |
topic | Online Articles: Clinical and Laboratory Observations |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9323561/ https://www.ncbi.nlm.nih.gov/pubmed/35622995 http://dx.doi.org/10.1097/MPH.0000000000002488 |
work_keys_str_mv | AT spasovneofitj firstlineantigd2therapycombinedwithconsolidationchemotherapyin3patientswithnewlydiagnosedmetastaticewingsarcomaorewinglikesarcoma AT dombrowskifrank firstlineantigd2therapycombinedwithconsolidationchemotherapyin3patientswithnewlydiagnosedmetastaticewingsarcomaorewinglikesarcoma AT lodeholgern firstlineantigd2therapycombinedwithconsolidationchemotherapyin3patientswithnewlydiagnosedmetastaticewingsarcomaorewinglikesarcoma AT spasovamariya firstlineantigd2therapycombinedwithconsolidationchemotherapyin3patientswithnewlydiagnosedmetastaticewingsarcomaorewinglikesarcoma AT ivanovaliliya firstlineantigd2therapycombinedwithconsolidationchemotherapyin3patientswithnewlydiagnosedmetastaticewingsarcomaorewinglikesarcoma AT mumdjievivan firstlineantigd2therapycombinedwithconsolidationchemotherapyin3patientswithnewlydiagnosedmetastaticewingsarcomaorewinglikesarcoma AT burnusuzovhassan firstlineantigd2therapycombinedwithconsolidationchemotherapyin3patientswithnewlydiagnosedmetastaticewingsarcomaorewinglikesarcoma AT siebertnikolai firstlineantigd2therapycombinedwithconsolidationchemotherapyin3patientswithnewlydiagnosedmetastaticewingsarcomaorewinglikesarcoma |